First-in-human Study of 7MW4911 in GI Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1/PHASE2

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-01-13

Study Completion Date

2028-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is the first-in-human study of 7MW4911 in US patients, to investigate its prelimary safety and efficacy in patients with gastrointestinal cancers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901

NCT04805307

Advanced Solid Tumor Gastric Cancer(Including Gastroesophageal Junction Adenocarcinoma) Pancreatic Cancer

COMPLETED PHASE1

To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors

NCT05260385

Digestive System Tumors

RECRUITING PHASE1/PHASE2

Exploratory Study on the S-1 + Paclitaxel Chemotherapy for Unresectable Gastric Cancer

NCT01756183

Surgically-Created Resection Cavity Drug Safety

UNKNOWN PHASE2

Intraperitoneal Chemotherapy Guided by the Detection of DNA in Peritoneal Lavage Fluid in Patients With Gastric Cancer

NCT05497739

Gastric Cancer

UNKNOWN PHASE2

Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors

NCT03507998

Colorectal Adenocarcinoma Gastric Adenocarcinoma Pancreatic Adenocarcinoma +4 more

UNKNOWN PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

GI Cancers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

7MW4911

Group Type EXPERIMENTAL

7MW4911

Intervention Type DRUG

study drug

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

7MW4911

study drug

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Aged 18 and above
2. ECOG 0-1
3. Life expectancy ≥ 3 months
4. Advanced or metastatic gastrointestinal cancer that has progressed after standard of care.
5. Disease progression after the most recent treatment regimen
6. At least one measurable lesion according to RECIST v1.1
7. Provision of archival tumor tissue or fresh biopsy.
8. Adequte hematologic funciton, liver function and renal function.
9. Comply with contraceptive requirements

Exclusion Criteria

1. Other concurrent malignancy in the recent 3 years except for adequately treated carcinoma in situ.
2. Active, untreated or symptomatic CNS metastasis
3. Effusions that require frequent drainage
4. Patients with active autoimmune disease, except for type I diabetes, hypothyroidism and other autoimmune disease that does not require systemic treatment.
5. Severe respiratory disease that required hospitalization in the last 28 days.
6. Significant and uncontrolled cardiovascular disease or events in the 6 months prior to study drug administration
7. Poorly controlled blood glucose with fasting blood glucose above 10mmol/L
8. Recipient of allogeneic stem cell transplant or organ transplant
9. Active HIV or hepatitis B/C infection. Infection requiring systemic IV in the 14 days prior to study drug administration.
10. Experiencing toxicities from prior anti-cancer therapies that have not recovered to CTCAE grade 0-1, except for alopecia and endocrinopathies.
11. Prohibited treatment and treatment that requires washout period

1. Has received another Topo-I payload ADC, and/or another CDH17 targeting therapy.
2. Received other cancer therapy within 5 half-lives or 21 days prior to study drug administration.
3. Major surgeries within 28 days prior to study drug administration
4. Investigational therapy within 28 days prior to study drug administration
5. Systemic treatment with immunosuppressive agents within 28 days prior to first drug administration. Physiological dose of glucocorticoid, topical glucocorticoid are allowed.
6. Use of strong CYP3A4 inhibitor or inducer
12. Known hypersensitivity to 7MW4911 or components of the formulation
13. Abuse of narcotic or psychoactive drugs
14. Pregnant or breastfeeding women
15. Other circumstances or conditions where the investigator judges to be unsuitable for study.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No